Multiple endocrine neoplasia type 1 (MEN1) is an autosomal-dominant disease caused by a mutation in the *MEN1* tumor-suppressor gene. Somatic mutations in *MEN1* also occur in 40% of nonfunctioning pancreatic neuroendocrine tumors (PNETs) and may be associated with disease aggressiveness \[[@B1]\]. The prevalence of MEN1 in postmortem studies was 0.25%. By the fifth decade of life, biochemical manifestations are present in 98% of patients with MEN1, and clinical manifestations are present in 80% \[[@B2]\]. The penetrance of pancreatic tumors is 30% to 70% \[[@B2]\]. Common manifestations seen in MEN1 include primary hyperparathyroidism, pituitary adenomas, and neuroendocrine tumors of the gastro-entero-pancreatic tract \[[@B2]\]. MEN1 is diagnosed on the basis of one of the following three criteria: (1) occurrence of two or more MEN1-associated tumors (pituitary, parathyroid, or gastro-entero-pancreatic tumors), (2) occurrence of one of the MEN1-associated tumors in a first-degree relative of a patient with a clinical diagnosis of one of the MEN1 manifestations, or (3) the presence of a germline *MEN1* mutation \[[@B2]\]. The *MEN1* gene locus is on chromosome 11q13 and encodes the menin protein \[[@B3]\]. As in other tumor suppressor--inherited cancer syndromes, a multistep model of "two hits" occurs, causing inactivating mutations in *MEN1*.

von Hippel-Lindau (VHL) disease is an autosomal-dominant disorder caused by a germline mutation in the tumor-suppressor gene *VHL*. It is located on chromosome 3p25.5 \[[@B4], [@B5]\]. The incidence of VHL is 1 in 36,000 live births with a penetrance of 95% at 65 years of age \[[@B5]\]. The clinical manifestation of VHL includes retinal hemangioblastomas, central nervous system hemangioblastomas, renal cystic and solid tumors, endolymphatic sac tumors, pheochromocytomas, cystic pancreatic lesions, and PNETs. PNETs are present in 11% to 17% of patients with VHL \[[@B5], [@B6]\]. Although both MEN1 and VHL may manifest with PNETs, no germline *MEN1* mutation with a coexisting somatic *VHL* mutation has been reported in the literature.

In sporadic PNETs, rates of somatic *MEN1* mutations have been reported as 13% to 44%, whereas rates of somatic *VHL* mutations have been reported as \<1% \[[@B7], [@B8]\]. With advances in next-generation sequencing, it is becoming possible to efficiently analyze driver mutations in cancer for precision medicine with targeted therapy. In patients with low- and intermediate-grade PNETs, there are various treatment options, including somatostatin analogues, sunitinib, everolimus, and peptide receptor radionuclide therapy. Sunitinib is a tyrosine kinase inhibitor that is active against multiple tyrosine kinase receptors, including *VEGFR*, *PDGFR*, *KIT*, *RET*, and FMS-like tyrosine kinase 3 (*FLT3*) \[[@B9]\]. Everolimus is a mammalian target of the rapamycin (mTOR) signaling pathway inhibitor and a derivative of rapamycin. It inhibits the PI3K/mTOR-raptor pathway, which regulates tumor cell proliferation and angiogenesis \[[@B9]\]. Both sunitinib and everolimus have shown significantly improved progression-free survival in patients with progressive metastatic neuroendocrine tumors, including PNETs, and both drugs are approved by the US Food and Drug Administration for this indication \[[@B10], [@B11]\]. However, it is unclear which patients with metastatic PNETs benefit from which agent.

Thus, we are conducting a phase II trial of mutation-targeted therapy with sunitinib or everolimus in patients with advanced low- or intermediate-grade neuroendocrine tumors of the gastrointestinal tract and pancreas with or without cytoreductive surgery (NCT02315625) to test whether the tumor genotype determines response to treatment \[[@B9]\]. As part of our clinical trial, tumor biopsy and mutational analysis by next-generation sequencing is performed. Patients with somatic or germline mutations in *MEN1/PDGFR/KIT/FLT3* or wild-type tumor are treated with sunitinib \[[@B9]\]. Patients with somatic or germline mutations in *NF1/PTEN/P13K/AKT/mTOR/VHL* are treated with everolimus. When there is disease progression, subjects cross over to treatment with the other medication. Treatment is discontinued in the case of disease progression after crossover, unacceptable toxicity, or withdrawal of consent \[[@B9]\]. Herein, we report on a patient who enrolled in this trial with a germline *MEN1* mutation and metastatic PNET who was also found to have a somatic *VHL* mutation that responded to sunitinib therapy.

1. Case Description {#s1}
===================

A 45-year-old woman with MEN1 presented with abdominal pain, distention, bloating, and diarrhea. Her medical history was notable for primary hyperparathyroidism, which required a 3.5-gland parathyroidectomy, a nonfunctioning pituitary adenoma (for which she had transphenoidal resection because of growth and associated mass effect on the internal carotid artery), and Zollinger-Ellison syndrome, for which she was treated with pantoprazole twice daily. She also had a history of well-differentiated metastatic pulmonary neuroendocrine tumors, for which she had a video-assisted thoracoscopic resection. Her family history was notable for a father, a brother, two paternal uncles, one paternal aunt, a paternal grandmother, and a son all diagnosed with MEN1. In June 2010, she presented with symptoms and biochemical evidence of pancreatitis.

A workup revealed an obstructing complex mass in the head of the pancreas and lesions in the tail of the pancreas and duodenum \[[Fig. 1(A](#F1){ref-type="fig"})\]. She underwent a pancreaticoduodenectomy and had an uncomplicated postoperative course. Pathology showed duodenal and retroperitoneal gastrinomas as well as a PNET. Lesions were well differentiated with a WHO grade 1 tumor and a pT2N0MX stage. Immunohistochemical staining of the tumor was positive for synaptophysin and chromogranin \[[Fig. 2(A) and 2(B](#F2){ref-type="fig"})\]. Immunohistochemistry was also performed for VHL (ab140989; Abcam, Cambridge, MA) and menin (ab2605; Abcam, Cambridge, MA) \[[Fig. 2(C) and 2(D](#F2){ref-type="fig"})\]. Although there was positive staining in the menin protein, menin is a nuclear protein, and localization to the cellular membrane, as shown in [Fig. 2(C)](#F2){ref-type="fig"}, is evidence of an abnormal protein \[[@B12]\]. VHL staining appears predominantly cytoplasmic in normal tissue \[[@B13]\]. As shown in [Fig. 2(D)](#F2){ref-type="fig"}, the neoplastic cells showed both nuclear and cytoplasmic staining.

![**(**A) Computed tomography scan (axial section) with contrast showing mass in the head of the pancreas (arrow) that abuts the superior mesenteric vein and the second/third portion of the duodenum.](js-01-1124-f1){#F1}

![Tumor immunohistochemistry. (A) Immunohistochemistry for synaptophysin (×20 magnification, brown color). (B) Immunohistochemistry for chromogranin (×20 magnification, brown color). (C) Immunohistochemistry for menin (×20 magnification, brown color) with an inset of normal pancreatic tissue (×40 magnification, brown color). (D) Immunohistochemistry for VHL (×20 magnification, brown color) with an inset of normal pancreatic tissue (×40 magnification, brown color).](js-01-1124-f2){#F2}

Follow-up imaging in June 2014 showed growth of the tumor in the body and tail of the pancreas, mesenteric lymph node, and three arterial-phase enhancing liver lesions \[[Fig. 3(A) and 3(B](#F3){ref-type="fig"})\]. She underwent transarterial chemoembolization procedures in August 2014, October 2014, and January 2015 for the liver lesions without response to treatment. Her pancreatic body tumor grew from 2.6 to 3.2 cm in greatest diameter.

###### 

**(**A) Computed tomography scans (axial section) of the abdomen with contrast showing enhancing mass along the dorsal aspect of the pancreas before and after treatment, decreasing from 3.1 cm at the greatest diameter to 2.5 cm, as well as a decrease in representative hepatic lesions (arrows). (B) Octreotide scan showing liver and peripancreatic uptake consistent with metastatic tumors (arrows). (C) DNA sequencing showing the same *MEN1* germline and somatic mutations. (D) *VHL* somatic nonsense mutation, c. 529A\>T. (E) Comparative genomic hybridization array showing LOH in chromosomes 3 and 11. (F) Sanger sequencing confirming the presence of c.402 deletion C, p.Phe134LeufsX51 *MEN1* and c.529A\>T, p.Arg177Ter VHL mutations.
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In July 2016, the patient was enrolled in the phase 2 trial Mutation-Targeted Therapy With Sunitinib or Everolimus in Patients With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery (NCT02315625). As part of the clinical trial, the patient's tumor DNA and RNA were sequenced and compared with peripheral blood DNA and RNA, respectively, for 500 known tumor suppressor and oncogenes. The OncoVar-NET assay (an oncogene panel sequencing analysis) was designed for the patient's GI NET tumor tissue by hybrid capture sequencing to validate somatic mutations identified in the coding regions of the following genes: PTEN, PIK3CA, AKT1, MTOR, VHL, TSC1, TSC2, NF1, TP53, MEN1, FLT3, PDGFRA, ATM, KIT, and ATRX. Peripheral blood served as a germline reference.

The sequencing results confirmed a germline *MEN1* mutation (deletion in exon 2, c.402 deletion C, p.Phe134LeufsX51), loss of heterozygosity (LOH) in the tumor tissue, and the same mutation in the other allele \[[Fig. 3(C) and 3(E](#F3){ref-type="fig"})\]. A somatic mutation in the *VHL* gene was identified, specifically a nonsense mutation c.529A\>T, p.Arg177Ter \[[Fig. 3(D) and 3(E](#F3){ref-type="fig"})\]. No other genetic alterations in genes associated with PNETs, such as *PTEN*, *PIK3CA*, *AKT1*, *MTOR*, *TSC1*, *TSC2*, *NF1*, *TP53*, *FLT3*, *PDGFRA*, *ATM*, *KIT*, and *ATRX*, were identified. Sanger sequencing confirmed the *MEN1* and *VHL* mutations noted in the original molecular profiling \[[Fig. 3(F)](#F3){ref-type="fig"}\]. The patient was treated with sunitinib and had response to treatment by November 2016 \[[Fig. 3(A](#F3){ref-type="fig"})\]. Of note, between the initiation of therapy and the response to treatment, our patient received no other therapy for her neuroendocrine tumors outside of sunitinib, and she remains on the same medication at the same dose.

2. Discussion {#s2}
=============

MEN1 and VHL are autosomal-dominant diseases with known susceptibility genes that cause PNETs. In both of these inherited syndromes, a second hit (somatic mutation) occurs in addition to the germline, resulting in multiorgan disease manifestation. Although secondary somatic mutations may occur in inherited tumor-suppressor cancer syndromes, a coexisting germline mutation in the tumor-suppressor gene with a somatic mutation in another tumor-suppressor gene responsible for an inherited syndrome has not been reported. Our patient presented with a known germline mutation in the *MEN1* gene and a family history of MEN1. She developed a metastatic PNET. She was enrolled in a clinical trial to assess whether the tumor genotyping was associated with a response to sunitinib and everolimus. Her previous clinical diagnosis of MEN1 was supported by her family history as well as by tumor genotyping using tumor tissue from her previous operative intervention, confirming the presence of a c.402 deletion C, p.Phe134LeufsX51 in *MEN1* in exon 2 with LOH in the *MEN1* locus in the tumor tissue; thus, she was started on sunitinib therapy. In addition, she had a coexisting somatic nonsense mutation in *VHL* gene c.529A\>T, p.Arg177Ter. A germline *MEN1* mutation with a somatic mutation in the tumor suppressor *VHL* has not been observed and may be a tumor genotype that is associated with aggressive PNETs.

Somatic *VHL* mutations in PNETs may be associated with metastatic progression \[[@B14]--[@B17]\]. In a study by Hessman *et al*. \[[@B18]\], LOH at 3p was observed in 45% of nonfamilial PNETs and in 36% of MEN1-associated PNETs. They also found that 92% of malignant tumors had allelic loss at 3p and 11q13 \[[@B18]\]. Possible *VHL* mutations associated with well-differentiated PNETs were found in one of 60 cases, according to a review of LOH studies in PNETs and gastrointestinal neuroendocrine tumors performed by Furlan *et al.* \[[@B17]\]. Lott *et al.* \[[@B16]\] found involvement of chromosome 3p in sporadic pancreatic islet cell tumorigenesis, with associated progression to malignancy. Chung *et al*. \[[@B19]\] demonstrated that both 3p and 11q (associated with *VHL* and *MEN1*, respectively) were commonly deleted loci in PNETs. Therefore, the combination of germline *MEN1* mutation and somatic *VHL* mutation may be associated with more aggressive disease. Furthermore, even in patients with a known germline mutation in either *VHL* or *MEN1*, tumor genotyping may reveal a somatic mutation that would allow the selection of the most appropriate agent to target the altered pathway(s).

In the case described, sunitinib therapy was selected because the patient had MEN1 and preclinical studies showed response to sunitinib therapy in transgenic mouse models of MEN1-associated PNETs \[[@B20]\]. The presence of a somatic mutation in *VHL* is associated with activation of the mTOR pathway; thus, everolimus treatment could be effective. However, VHL is associated with major tumor angiogenesis, which may explain why the patient had a response to sunitinib therapy \[[@B21], [@B22]\].

The case described illustrates that therapy selection based on tumor genotype in practice needs to be tested in clinical trials. Although "precision" treatment is selected according to the driver mutation(s) present and the expected pathway to be activated, response to treatment may be determined by the presence of coexisting mutations. Thus, in the current clinical trial in which the patient is enrolled, subjects who do not respond to one agent on the basis of the tumor genotype or presence of germline mutation are crossed over to treatment with the other agent to determine the important tumor genotype that predicts response to a selected agent.

Abbreviations: FLT3FMS-like tyrosine kinase 3LOHloss of heterozygosityMEN1multiple endocrine neoplasia type 1mTORmammalian target of the rapamycinPNETpancreatic neuroendocrine tumorVHLvon Hippel-Lindau.
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